Mechanisms of aflatoxin carcinogenesis.

Much progress has been made in elucidating the biochemical and molecular mechanisms that underlie aflatoxin carcinogenesis. In humans, biotransformation of AFB1 to the putative carcinogenic intermediate. AFB-8,9-exo-epoxide, occurs predominantly by cytochromes P450 1A2 and 3A4, with the relative importance of each dependent upon the relative magnitude of expression of the respective enzymes in liver. Genetic variability in the expression of these and other cytochromes P450 may result in substantial interindividual differences in susceptibility to the carcinogenic effects of aflatoxins. Detoxification of AFB-8,9-epoxide by a specific alpha class glutathione S-transferase is an important protective mechanism in mice, and it accounts for the resistance of this species to the carcinogenic effects of AFB. This particular form of GST is expressed constitutively only at low levels in rats, but it is inducible by antioxidants such as ethoxyquin, and it accounts for much of the chemoprotective effects of a variety of substances, including natural dietary components that putatively act via an "antioxidant response element" (ARE). In humans, the constitutively expressed GSTs have very little activity toward AFB1-8,9-exo-epoxide, suggesting that--on a biochemical basis--humans should be quite sensitive to the genotoxic effects of aflatoxins. If a gene encoding a high aflatoxin-active form of GST is present in the human genome, but is not constitutively expressed, and is inducible by dietary antioxidants (as occurs in rats), then chemo- and/or dietary intervention measures aimed at inducing this enzyme could be highly effective. However, as it is possible that human CYP 1A2 may also be inducible by these same chemicals (because of the possible presence of an ARE in this gene), the ultimate consequence of dietary treatment with chemicals that induce biotransformation enzymes via an ARE is uncertain. The balance of the rate of activation (exo-epoxide production) to inactivation (GST conjugation plus other P450-mediated non-epoxide oxidations) may be a strong indicator of individual and species susceptibility to aflatoxin carcinogenesis, if the experimental conditions are reflective of true dietary exposures. There is strong evidence that AFB-8,9-exo-epoxide binds to G:C rich regions of DNA, forming an adduct at the N7-position of guanine. Substantial evidence demonstrates that AFB1-8,9-epoxide can induce activating mutations in the ras oncogene in experimental animals, primarily at codon 12.(ABSTRACT TRUNCATED AT 400 WORDS)

[1]  J. Hendricks,et al.  Aflatoxicol-induced hepatocellular carcinoma in rainbow trout (Salmo gairdneri) and the synergistic effects of cyclopropenoid fatty acids. , 1981, Cancer research.

[2]  G. Wogan,et al.  Carcinogenic effects of low dietary levels of aflatoxin B1 in rats. , 1974, Food and cosmetics toxicology.

[3]  C R Dichter,et al.  Risk estimates of liver cancer due to aflatoxin exposure from peanuts and peanut products. , 1984, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[4]  L W Wattenberg,et al.  Inhibition of chemical carcinogenesis. , 1978, Journal of the National Cancer Institute.

[5]  K. Anderson,et al.  Enhanced phenacetin metabolism in human subjects fed charcoal‐broiled beef , 1976, Clinical pharmacology and therapeutics.

[6]  D. Eaton,et al.  7 – Role of Aflatoxin–DNA Adducts in the Cancer Process , 1993 .

[7]  G. Mcmahon,et al.  Characterization of c-Ki-ras oncogene alleles by direct sequencing of enzymatically amplified DNA from carcinogen-induced tumors. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[8]  L. Bjeldanes,et al.  Effect of dietary indole-3-carbinol on intestinal and hepatic monooxygenase, glutathione S-transferase and epoxide hydrolase activities in the rat. , 1984, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[9]  R. Krell,et al.  Inhibition by REV-5901 of leukotriene release from guinea-pig and human lung tissue in vitro. , 1989, Biochemical pharmacology.

[10]  T. Kensler,et al.  13 – Strategies for Chemoprotection against Aflatoxin-Induced Liver Cancer , 1993 .

[11]  J. Essigmann,et al.  Structural identification of the major DNA adduct formed by aflatoxin B1 in vitro. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[12]  P. Laurent-Puig,et al.  Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma , 1992, Hepatology.

[13]  D. Eaton,et al.  Identification of a novel dihydroxy metabolite of aflatoxin B1 produced in vitro and in vivo in rats and mice. , 1988, Chemical research in toxicology.

[14]  F. Guengerich,et al.  Glutathione conjugation of aflatoxin B1 exo- and endo-epoxides by rat and human glutathione S-transferases. , 1992, Chemical research in toxicology.

[15]  J. Yager,et al.  Protection by 5-(2-pyrazinyl)-4-methyl-1,2-dithiol-3-thione (oltipraz) against the hepatotoxicity of aflatoxin B1 in the rat. , 1988, Toxicology and applied pharmacology.

[16]  T. Shimada,et al.  Oxidation of aflatoxins and sterigmatocystin by human liver microsomes: significance of aflatoxin Q1 as a detoxication product of aflatoxin B1. , 1992, Chemical research in toxicology.

[17]  G. Mcmahon,et al.  Characterization of c-Ki-ras and N-ras oncogenes in aflatoxin B1-induced rat liver tumors. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[18]  A. Boobis,et al.  Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. , 1990, British journal of clinical pharmacology.

[19]  I. Weinstein,et al.  Cells that overproduce protein kinase C are more susceptible to transformation by an activated H-ras oncogene , 1989, Molecular and cellular biology.

[20]  R. Sinnhuber,et al.  Effect of cyclopropenoid compounds on the carcinogenic activity of diethylnitrosamine and aflatoxin B1 in rats. , 1974, Journal of the National Cancer Institute.

[21]  L. Bernstein,et al.  Summary of carcinogenic potency and positivity for 492 rodent carcinogens in the carcinogenic potency database. , 1989, Environmental health perspectives.